|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||-7.57|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BEVERLY, Mass., June 07, 2017-- Cellceutix Corporation,, an emerging biopharmaceutical company, is pleased to announce to shareholders, and the public at large, that the company name is changing to Innovation ...
BEVERLY, Mass., May 30, 2017-- Cellceutix Corporation,, is pleased to share further data supporting the p53 mechanism of action of Kevetrin and its treatment potential in Acute Myeloid Leukemia at the ...
BEVERLY, Mass., May 18, 2017-- Cellceutix Corporation,, is pleased to announce that patient enrollment has been completed in the third and final cohort of its Phase 2 open-label, Proof-of-Concept clinical ...